American Gene Technologies International has filed a notice of an exempt offering of securities to raise $10 Million in New Funding.
According to filings with the U.S. Securities and Exchange Commission, American Gene Technologies International Inc. is raising up to $10,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About American Gene Technologies International Inc.
American Gene Technologies has developed patent-protected gene therapies for medical breakthroughs. We are actively pursuing clinical cures for complex diseases. American Gene Technologies, a clinical-stage biotechnology company based in Rockville, Maryland, has recorded data that meets the primary and secondary endpoints of its AGT103-T Phase 1 trial. So much money has been poured into treating diseases, but far less into actually curing them. The pharmaceutical industry has done an incredible job of developing highly profitable treatments for a wide range of diseases and conditions.
To learn more about American Gene Technologies International Inc., visit https://www.americangene.com/
American Gene Technologies International Inc. Linkedin Page: https://www.linkedin.com/company/american-gene-technologies-international-inc/
Contact:
Jeffrey Galvin, Chief Executive Officer
301-337-2100
https://www.linkedin.com/in/jeff-galvin-60258/
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.
